Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen's Tezspire (tezepelumab) significantly reduced nasal polyp severity.
Johnson & Johnson has announced data from the Phase 3 ASTRO study of TREMFYA (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC).
CluePoints, provider of statistical and AI-driven software solutions, has been shortlisted for “Team Excellence in the Management of Clinical Data” at the 2025 ACDM Awards.
ITM has announced positive topline results from its Phase 3 COMPETE trial in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
NEC Bio Therapeutics presents 24-week promising interim results from an ongoing Phase 1 basket clinical trial of an orally administered cancer vaccine, NECVAX-NEO1.
iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, provides a clinical update on its lead asset, roginolisib.
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the close of a Series B extension financing round with an investment from EQT Life Sciences.
Ellipses Pharma has published the latest data from an ongoing Phase 1/2 clinical trial of EP0042, an orally available novel agent that targets the Aurora kinase axis, in patients with acute myeloid leukaemia (AML).
Everest Medicines has announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011).
